

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	168	c1Q adj domain	US-PGPUB; USPAT; DERWENT	OR	ON	2006/09/05 16:04
L2	165	c1Q adj domain and polypeptide	US-PGPUB; USPAT; DERWENT	OR	ON	2006/09/05 16:05
L3	160	c1Q adj domain and polypeptide and dna	US-PGPUB; USPAT; DERWENT	OR	ON	2006/09/05 16:05
L4	1	human adj c1Q adj domain and polypeptide and dna	US-PGPUB; USPAT; DERWENT	OR	ON	2006/09/05 16:06

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptamym1652

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS 5 MAY 11 KOREAPAT updates resume
NEWS 6 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 7 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and
USPATFULL/USPAT2
NEWS 8 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS
NEWS 9 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 10 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 11 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12 JUL 11 CHEMSAFE reloaded and enhanced
NEWS 13 JUL 14 FSTA enhanced with Japanese patents
NEWS 14 JUL 19 Coverage of Research Disclosure reinstated in DWPI
NEWS 15 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 16 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 17 AUG 30 CA(SM)/CAPLUS(SM) Austrian patent law changes

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:10:33 ON 05 SEP 2006

=> file .mymstn

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 16:10:54 ON 05 SEP 2006

FILE 'AGRICOLA' ENTERED AT 16:10:54 ON 05 SEP 2006

FILE 'JICST-EPLUS' ENTERED AT 16:10:54 ON 05 SEP 2006
COPYRIGHT (C) 2006 Japan Science and Technology Agency (JST)

FILE 'BIOSIS' ENTERED AT 16:10:54 ON 05 SEP 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 16:10:54 ON 05 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'LIFESCI' ENTERED AT 16:10:54 ON 05 SEP 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHNO' ENTERED AT 16:10:54 ON 05 SEP 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'EMBASE' ENTERED AT 16:10:54 ON 05 SEP 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

=> s human (w) clq
L1 903 HUMAN (W) ClQ

=> s l1 and polypeptide
L2 42 L1 AND POLYPEPTIDE

=> s l2 and domain
L3 8 L2 AND DOMAIN

=> s l3 and dna
L4 2 L3 AND DNA

=> d ibib abs l4 1-2

L4 ANSWER 1 OF 2 MEDLINE on STN
ACCESSION NUMBER: 85038855 MEDLINE
DOCUMENT NUMBER: PubMed ID: 6208566
TITLE: Cloning and characterization of the complementary
DNA for the B chain of normal human serum Clq.
AUTHOR: Reid K B; Bentley D R; Wood K J
SOURCE: Philosophical transactions of the Royal Society of London.
Series B, Biological sciences, (1984 Sep 6) Vol. 306, No.
1129, pp. 345-54.
Journal code: 7503623. ISSN: 0962-8436.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198411
ENTRY DATE: Entered STN: 20 Mar 1990
Last Updated on STN: 29 Jan 1999
Entered Medline: 28 Nov 1984

AB Normal human Clq is a serum glycoprotein of 460 kDa
containing 18 polypeptide chains (6A, 6B, 6C) each 226 amino
acids long and each containing an N-terminal collagen-like domain
and a C-terminal globular domain. Two unusual forms of Clq have
been described: a genetically defective form, which has a molecular mass
of approximately 160 kDa and is found in the sera of homozygotes for the
defect who show a marked susceptibility to immune complex related disease;

a fibroblast form, shown to be synthesized and secreted, in vitro, with a molecular mass of about 800 kDa and with chains approximately 16 kDa greater than those of normal Clq. A higher than normal molecular mass form of Clq has also been described in human colostrum and a form of Clq has been claimed to represent one of the types of Fc receptor on guinea-pig macrophages. To initiate studies, at the genomic level, on these various forms of Clq, and to investigate the possible relation between the Clq genes and the procollagen genes, the complementary DNA corresponding to the B chain of normal Clq has been cloned and characterized.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:824432 CAPLUS

DOCUMENT NUMBER: 143:222523

TITLE: Protein and cDNA sequences for human
Clq domain-containing TNF α
family protein ClQ/TNF7 that increases both fatty and
lean body mass, and therapeutic uses

INVENTOR(S): Emtage, Peter C. r.; Liu, Shouchun; Thai, Kerri

PATENT ASSIGNEE(S): Nuvelo, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 94 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005180949	A1	20050818	US 2005-57027	20050211
WO 2006028492	A2	20060316	WO 2005-US4621	20050211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2004-544806P P 20040213

AB The invention relates to pharmaceutical compns. comprising human ClQ/TNF7 (hClQ/TNF7) polynucleotides and polypeptides. The present invention is based on the discovery that hClQ/TNF7 increases body mass, both fatty and lean body mass. The invention provides proteins and cDNA sequences for hClQ/TNF7. HClQ/TNF7 is a Clq domain -containing protein that also shares homol. to TNF α . HClQ/TNF7 is identical to protein CTRP7 (complement-Clq tumor necrosis factor-related protein 7) (AAK17963). HClQ/TNF7 homologous to adiponectin and murine ClQ/TNF2. The hClQ/TNF7 polypeptide of SEQ ID NO: 4 is an approx. 289 amino acid protein with a predicted mol. mass of approx. 31.7 kDa unglycosylated, and a predicted signal peptide. Thus, compns. comprising hClQ/TNF7, fragments or analogs thereof, may be used for the treatment of conditions where an increase in body mass is required, such as for the treatment of wasting disorders, such as cachexia, eating disorders, or diseases with a growth deficiency, such as genetic dwarfism or the growth retardation associated with pediatric Crohn's disease.

=> d 13 ibib abs 1-8

L3 ANSWER 1 OF 8 MEDLINE on STN

ACCESSION NUMBER: 85038855 MEDLINE
DOCUMENT NUMBER: PubMed ID: 6208566
TITLE: Cloning and characterization of the complementary DNA for the B chain of normal human serum Clq.
AUTHOR: Reid K B; Bentley D R; Wood K J
SOURCE: Philosophical transactions of the Royal Society of London. Series B, Biological sciences, (1984 Sep 6) Vol. 306, No. 1129, pp. 345-54.
Journal code: 7503623. ISSN: 0962-8436.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198411
ENTRY DATE: Entered STN: 20 Mar 1990
Last Updated on STN: 29 Jan 1999
Entered Medline: 28 Nov 1984

AB Normal human Clq is a serum glycoprotein of 460 kDa containing 18 polypeptide chains (6A, 6B, 6C) each 226 amino acids long and each containing an N-terminal collagen-like domain and a C-terminal globular domain. Two unusual forms of Clq have been described: a genetically defective form, which has a molecular mass of approximately 160 kDa and is found in the sera of homozygotes for the defect who show a marked susceptibility to immune complex related disease; a fibroblast form, shown to be synthesized and secreted, in vitro, with a molecular mass of about 800 kDa and with chains approximately 16 kDa greater than those of normal Clq. A higher than normal molecular mass form of Clq has also been described in human colostrum and a form of Clq has been claimed to represent one of the types of Fc receptor on guinea-pig macrophages. To initiate studies, at the genomic level, on these various forms of Clq, and to investigate the possible relation between the Clq genes and the procollagen genes, the complementary DNA corresponding to the B chain of normal Clq has been cloned and characterized.

L3 ANSWER 2 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 1980:251528 BIOSIS
DOCUMENT NUMBER: PREV198070044024; BA70:44024
TITLE: COMPLEMENT C-1 FROM THE BULL FROG RANA-CATESBEIANA
FUNCTIONAL PROPERTIES OF ACTIVATED COMPLEMENT C-1 AND
ISOLATION OF COMPLEMENT C-1Q.
AUTHOR(S): ALEXANDER R J [Reprint author]; STEINER L A
CORPORATE SOURCE: DEP BIOL, MASS INST TECHNOL, CAMBRIDGE, MASS 02139, USA
SOURCE: Journal of Immunology, (1980) Vol. 124, No. 3, pp. 1418-1425.
CODEN: JOIMA3. ISSN: 0022-1767.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: ENGLISH

AB A euglobulin fraction of bullfrog (R. catesbeiana) serum can replace a similar fraction of guinea pig serum in the standard assay for C.hivin.1, the activated 1st component of complement. In this assay, sheep erythrocytes sensitized with rabbit antibodies and coated with guinea pig C4 (EAC4gp) are reacted with the C.hivin.1-containing test sample and then with guinea pig C2 and C3-9. This finding, together with earlier observations that some frog antibodies interact with guinea pig C and C.hivin.1, suggested that the C1 components in frogs and in mammals might be similar in structure. C1 is a complex of 3 subcomponents; one of these, Clq, binds to immunoglobulins and activates Clr, which activates C1s, triggering the classical C cascade. Clq, isolated from human serum, is an unusual protein, having globular and collagen-like regions. To determine whether frog Clq has a similar structure, this protein was isolated from frog serum by methods similar to those used in the isolation of human Clq. The activity of frog Clq was measured

by substituting it for human Clq in an assay utilizing human ****GRAPHIC****. and ****GRAPHIC****. EAC4gp, and guinea pig C2 and C3-9. By gel filtration, frog Clq seems to be similar in overall size to human Clq. As judged by polyacrylamide gel electrophoresis, the subunit structure of the 2 proteins is similar, with pairs of polypeptide chains cross-linked by disulfide bridges. Like the human protein, frog Clq contains the unusual amino acids, hydroxyproline and hydroxylysine, and is rich in glycine, suggesting that it has a collagen-like domain. Frog and human Clq apparently are very similar, although not identical, in structure. The characteristic features of this protein, which forms a link between the immune and C systems, may have been preserved in evolution, at least since the appearance of the class Amphibia.

L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:824432 CAPLUS
 DOCUMENT NUMBER: 143:222523
 TITLE: Protein and cDNA sequences for human Clq domain-containing TNF α family protein ClQ/TNF7 that increases both fatty and lean body mass, and therapeutic uses
 INVENTOR(S): Emtage, Peter C. r.; Liu, Shouchun; Thai, Kerri
 PATENT ASSIGNEE(S): Nuvelo, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 94 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005180949	A1	20050818	US 2005-57027	20050211
WO 2006028492	A2	20060316	WO 2005-US4621	20050211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2004-544806P P 20040213
 AB The invention relates to pharmaceutical compns. comprising human ClQ/TNF7 (hClQ/TNF7) polynucleotides and polypeptides. The present invention is based on the discovery that hClQ/TNF7 increases body mass, both fatty and lean body mass. The invention provides proteins and cDNA sequences for hClQ/TNF7. HClQ/TNF7 is a Clq domain -containing protein that also shares homol. to TNF α . HClQ/TNF7 is identical to protein CTRP7 (complement-Clq tumor necrosis factor-related protein 7) (AAK17963). HClQ/TNF7 homologous to adiponectin and murine ClQ/TNF2. The hClQ/TNF7 polypeptide of SEQ ID NO: 4 is an approx. 289 amino acid protein with a predicted mol. mass of approx. 31.7 kDa unglycosylated, and a predicted signal peptide. Thus, compns. comprising hClQ/TNF7, fragments or analogs thereof, may be used for the treatment of conditions where an increase in body mass is required, such as for the treatment of wasting disorders, such as cachexia, eating disorders, or diseases with a growth deficiency, such as genetic dwarfism or the growth retardation associated with pediatric Crohn's disease.

L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:811266 CAPLUS
DOCUMENT NUMBER: 130:262847
TITLE: Cloning and characterization of CRF, a novel
Clq-related factor, expressed in areas of the brain
involved in motor function
AUTHOR(S): Berube, Nathalie G.; Swanson, Xin H.; Bertram, Michael
J.; Kittle, Joseph D.; Didenko, Vladimir; Baskin,
David S.; Smith, James R.; Pereira-Smith, Olivia M.
CORPORATE SOURCE: Departments of Cell Biology and Medicine, Division of
Molecular Virology, Roy M. and Phyllis Gough
Huffington Center on Aging, Baylor College of
Medicine, Houston, TX, 77030-3498, USA
SOURCE: Molecular Brain Research (1999), 63(2), 233-240
CODEN: MBREE4; ISSN: 0169-328X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We have isolated and characterized a novel cDNA, Clq-Related Factor (CRF),
that is predicted to encode a 258 amino acid polypeptide with a
hydrophobic signal sequence, a collagenous region, and a globular
domain at the carboxy terminus that shares homol. to the Clq
signature domain. Human CRF transcript is expressed at highest
levels in the brain, particularly in the brainstem. In situ hybridization
to mouse brain sections demonstrated that CRF transcripts are most
abundant in areas of the nervous system involved in motor function, such
as the Purkinje cells of the cerebellum, the accessory olivary nucleus,
the pons and the red nucleus. The mouse CRF homolog is highly similar to
the human gene at both the nucleotide and protein level, suggesting an
important conserved role for this protein.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1980:405753 CAPLUS
DOCUMENT NUMBER: 93:5753
TITLE: The first component of complement from the bullfrog,
Rana catesbeiana: functional properties of C.hivin.1
and isolation of subcomponent Clq
AUTHOR(S): Alexander, Richard J.; Steiner, Lisa A.
CORPORATE SOURCE: Dep. Biol., Massachusetts Inst. Technol., Cambridge,
MA, 02139, USA
SOURCE: Journal of Immunology (1980), 124(3), 1418-25
CODEN: JOIMA3; ISSN: 0022-1767
DOCUMENT TYPE: Journal
LANGUAGE: English

AB An euglobulin fraction of bullfrog serum could replace a similar fraction
of guinea pig serum in the standard assay for complement C.hivin.1.
Complement Clq was isolated from frog serum by methods similar to those
used in the isolation of human Clq. The activity of
frog Clq was measured by substituting it for human Clq
in an assay utilizing human C.hivin.1.hivin.r and C.hivin.1.hivin.s,
EAC4gP, and guinea pig C2 and C3-9. By gel filtration, frog Clq seems to
be similar in overall size to human Clq. As judged by
polyacrylamide gel electrophoresis, the subunit structure of the 2
proteins also appears to be similar, with pairs of polypeptide
chains cross-linked by disulfide bridges. Like the human protein, frog
Clq contained hydroxyproline and hydroxylysine, and is rich in glycine,
suggesting that it also has a collagen-like domain. The
combined evidence indicates that frog and human Clq
are very similar, although not identical, in structure. Apparently, the
characteristic features of this protein, which forms a link between the
immune and C systems, have been preserved in evolution, at least since the
appearance of the class Amphibia.

L3 ANSWER 6 OF 8 LIFESCI COPYRIGHT 2006 CSA on STN

ACCESSION NUMBER: 1999:110111 LIFESCI

TITLE: Assignment of the gene encoding mannan-binding lectin-associated serine protease 2 (MASP2) to human chromosome 1p36.3 arrow right p36.2 by in situ hybridization and somatic cell hybrid analysis

AUTHOR: Stover, C.M.; Schwaeble, W.J.; Lynch, N.J.; Thiel, S.; Speicher, M.R.

CORPORATE SOURCE: Department of Microbiology and Immunology, University of Leicester, University Road, Leicester LE1 9HN, UK; E-mail: ws5@le.ac.uk

SOURCE: Cytogenetics and Cell Genetics [Cytogenet. Cell Genet.], (19990000) vol. 84, no. 3-4, pp. 148-149. ISSN: 0301-0171.

DOCUMENT TYPE: Journal

FILE SEGMENT: G

LANGUAGE: English

AB The complement system is an important constituent of the innate immune defense. It can be activated via an immune complex mediated "classical" activation pathway and by two antibody independent activation routes termed the alternative and the mannan-binding lectin activation pathways. The latter is composed of a multimolecular complex formed by hexameric mannan-binding lectin (MBL), a plasma collectin, two mannan-binding lectin-associated serine proteases, termed MASP1 and MASP2, and an MASP2 related plasma protein, termed MAP19. MASP1 has been referred to as CRARF. Crarf MASP and PR555 in various publications and databases. The architecture of MBL, MASP1, and MASP2 resembles that of the constituents of the C1 complex of the classical activation pathway. The latter consists of hexameric C1q and the serine proteases C1r and C1s. The four serine proteases, MASP1, MASP2, C1r, and C1s are multimodular proteins which have a similarity score of 39 to 50%. Among them, MASP2 and C1s are the C4 cleaving components. MAP19 is expected to be enzymatically inactive as it lacks the serine protease domain and consists only of the two N-terminal domain motifs of MASP2. It was shown to arise by an alternative splicing/polyadenylation mechanism together with MASP2 from a single structural gene. MAP19 may have a modulating role in the activation of complement via the lectin pathway. Phylogenetically, the lectin pathway of complement activation antedates the emergence of the classical or alternative activation routes as MASP1 homologous sequences were identified in ascidian. Chromosome locations in human have been determined for the three genes encoding the three different polypeptide chains for human C1q, located on chromosome 1p36.3 arrow right p34.1. The genes coding for the C1q-associated serine proteases C1r and C1s are closely linked on chromosome 12p13 and are thought to have arisen by gene duplication from a common ancestor. The gene coding for MBL has been mapped to human chromosome 10q11.2 arrow right q21. The gene for MASP1 has been localized to human chromosome 3q27 arrow right q28. This study assigns the gene encoding MASP2 and MAP19 to human chromosome 1p36.3 arrow right p36.2.

L3 ANSWER 7 OF 8 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN

ACCESSION NUMBER: 1980:10135997 BIOTECHNO

TITLE: The first component of complement from the bullfrog, *Rana catesbeiana*: Functional properties of C1 and isolation of subcomponent C1q

AUTHOR: Alexander R.J.; Steiner L.A.

CORPORATE SOURCE: Dept. Biol., MIT, Cambridge, Mass. 02139, United States.

SOURCE: Journal of Immunology, (1980), 124/3 (1418-1425)
CODEN: JOIMA3

DOCUMENT TYPE: Journal; Article

COUNTRY: United States

LANGUAGE: English

AN 1980:10135997 BIOTECHNO

AB We have found that a euglobulin fraction of bullfrog (*Rana catesbeiana*) serum can replace a similar fraction of guinea pig serum in the standard assay for C1, the activated first component of complement (C). In this assay, sheep erythrocytes sensitized with rabbit antibodies and coated with guinea pig C4 (EAC4(gp)), are reacted with the C1-containing test sample and then with guinea pig C2 and C3-9. This finding, together with earlier observations that some frog antibodies interact with guinea pig C and C1, suggested that the C1 components in frogs and in mammals might be similar in structure. C1 is a complex of three subcomponents; one of these, Clq, binds to immunoglobulins and activates C1r, which, in turn, activates C1s, thereby triggering the classical C cascade. Clq, isolated from human serum, is an unusual protein, having both globular and collagen-like regions. To determine whether frog Clq has a similar structure, we isolated this protein from frog serum by methods similar to those used in the isolation of human Clq. The activity of frog Clq was measured by substituting it for human Clq in an assay utilizing human C1r and C1s, EAC4(gp), and guinea pig C2 and C3-9. By gel filtration, frog Clq seems to be similar in overall size to human Clq. As judged by polyacrylamide gel electrophoresis, the subunit structure of the two proteins also appears to be similar, with pairs of polypeptide chains cross-linked by disulfide bridges. Like the human protein, frog Clq contains the unusual amino acids, hydroxyproline and hydroxylysine, and is rich in glycine, suggesting that it also has a collagen-like domain. The combined evidence indicates that frog and human Clq are very similar, although not identical, in structure. It seems that the characteristic features of this protein, which forms a link between the immune and C systems, have been preserved in evolution, at least since the appearance of the class Amphibia.

L3 ANSWER 8 OF 8 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 80105239 EMBASE

DOCUMENT NUMBER: 1980105239

TITLE: The first component of complement from the bullfrog, *Rana catesbeiana*: Functional properties of C1 and isolation of subcomponent Clq.

AUTHOR: Alexander R.J.; Steiner L.A.

CORPORATE SOURCE: Dept. Biol., MIT, Cambridge, Mass. 02139, United States

SOURCE: Journal of Immunology, (1980) Vol. 124, No. 3, pp. 1418-1425.

CODEN: JOIMA3

COUNTRY: United States

DOCUMENT TYPE: Journal

FILE SEGMENT: 026 Immunology, Serology and Transplantation

LANGUAGE: English

ENTRY DATE: Entered STN: 9 Dec 1991

Last Updated on STN: 9 Dec 1991

AB We have found that a euglobulin fraction of bullfrog (*Rana catesbeiana*) serum can replace a similar fraction of guinea pig serum in the standard assay for C1, the activated first component of complement (C). In this assay, sheep erythrocytes sensitized with rabbit antibodies and coated with guinea pig C4 (EAC4(gp)), are reacted with the C1-containing test sample and then with guinea pig C2 and C3-9. This finding, together with earlier observations, that some frog antibodies interact with guinea pig C and C1, suggested that the C1 components in frogs and in mammals might be similar in structure. C1 is a complex of three subcomponents; one of these, Clq, binds to immunoglobulins and activates C1r, which, in turn, activates C1s, thereby triggering the classical C cascade. Clq, isolated from human serum, is an unusual protein, having both globular and collagen-like regions. To determine whether frog Clq has a similar structure, we isolated this protein from frog serum by methods similar to those used in the isolation of human Clq. The activity of frog Clq was measured by substituting it for human

Clq in an assay utilizing human Clr and Cls, EAC4(gp), and guinea pig C2 and C3-9. By gel filtration, frog Clq seems to be similar in overall size to human Clq. As judged by polyacrylamide gel electrophoresis, the subunit structure of the two proteins also appears to be similar, with pairs of polypeptide chains cross-linked by disulfide bridges. Like the human protein, frog Clq contains the unusual amino acids, hydroxyproline and hydroxylysine, and is rich in glycine, suggesting that it also has a collagen-like domain. The combined evidence indicates that frog and human Clq are very similar, although not identical, in structure. It seems that the characteristic features of this protein, which forms a link between the immune and C systems, have been preserved in evolution, at least since the appearance of the class Amphibia.